The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A pilot presurgical study evaluating anti-PD-L1 durvalumab (durva) plus anti-CTLA-4 tremelimumab (treme) in patients (pts) with high-risk muscle-invasive bladder carcinoma (MIBC) who are ineligible for cisplatin-based neoadjuvant chemotherapy (NAC).
 
Jianjun Gao
Travel, Accommodations, Expenses - AstraZeneca
 
Arlene O. Siefker-Radtke
Consulting or Advisory Role - AstraZeneca; Bavarian Nordic; BioClin Therapeutics; Bristol-Myers Squibb; EMD Serono; Genentech; Inovio Pharmaceuticals; Janssen; Lilly; Merck; NCCN; Nektar; Seagen
Research Funding - BioClin Therapeutics; Bristol-Myers Squibb; Janssen; Michael and Sherry Sutton Fund for Urothelial Cancer; Nektar; NIH; Takeda
Patents, Royalties, Other Intellectual Property - Methods of characterizing and treating molecular subsets of muscle-invasive bladder cancer.
 
Neema Navai
No Relationships to Disclose
 
Matthew T Campbell
Honoraria - Eisai; EMD Serono; Genentech/Roche; Pfizer; Taiho Pharmaceutical
Consulting or Advisory Role - Apricity Health; AstraZeneca; Eisai; EMD Serono; Genentech; Novartis; Pfizer
Research Funding - Exelixis
 
Rebecca Slack Tidwell
No Relationships to Disclose
 
Charles Guo
No Relationships to Disclose
 
Ashish M. Kamat
Honoraria - AstraZeneca (I); Tesaro (I)
Consulting or Advisory Role - Abbott Molecular; Arquer Diagnostics; Bristol-Myers Squibb; CG Oncology; Eisai; Ferring; Heat Biologics; Imagin Medical; Merck; Photocure; Theralase; US Biotest
Research Funding - Bristol-Myers Squibb; FKD Therapies; Heat Biologics; Merck; Photocure
Patents, Royalties, Other Intellectual Property - Patent: CyPRIT (Cytokine Predictors of Response to Intravesical Therapy) joint with UT MD Anderson Cancer Center
Other Relationship - International Bladder Cancer Group (IBCG)
 
Surena F. Matin
Honoraria - C-SATS; Peloton Therapeutics; Taris BioMedical; Urogen pharma
Consulting or Advisory Role - C-SATS; Peloton Therapeutics; Theracoat; Urogen pharma
Research Funding - AT&T
 
John C. Araujo
No Relationships to Disclose
 
Amishi Yogesh Shah
Honoraria - Eisai; Oncology Information Group
Research Funding - Bristol-Myers Squibb; Eisai; EMD Serono
 
Pavlos Msaouel
Research Funding - Bristol-Myers Squibb (Inst); Mirati Therapeutics (Inst); Takeda (Inst)
 
Jorge M. Blando
No Relationships to Disclose
 
Luis M. Vence
No Relationships to Disclose
 
Fei Duan
No Relationships to Disclose
 
Sreyashi Basu
No Relationships to Disclose
 
Shalini Singh
No Relationships to Disclose
 
Hao Zhao
No Relationships to Disclose
 
James Patrick Allison
Patents, Royalties, Other Intellectual Property - Inventor of a patent held by the University of California, Berkeley, and licensed to Bristol Meyers-Squibb; Inventor of a patent owned by Memorial Sloan-Kettering Cancer Center and licensed by Jounce Therapeutics
 
Colin P.N. Dinney
Consulting or Advisory Role - FKD Therapies; Merck; NCI
Research Funding - FKD Therapies; Merck; NCI; University of Eastern Finland (Inst)
 
Padmanee Sharma
Stock and Other Ownership Interests - Apricity Health; Apricity Health (I); BioAtla; BioAtla (I); Codiak Biosciences; Codiak Biosciences (I); Constellation Pharmaceuticals; Forty Seven; Forty Seven (I); Hummingbird; Hummingbird (I); ImaginAb; ImaginAb (I); Jounce Therapeutics; Jounce Therapeutics (I); Marker Therapeutics; Marker Therapeutics (I); Neon Therapeutics; Neon Therapeutics (I); Oncolytics; Polaris; Polaris (I); TapImmune Inc.; TapImmune Inc. (I); Tvardi Therapeutics (I)
Consulting or Advisory Role - Amgen (I); Apricity Health; Apricity Health (I); BioAtla; BioAtla (I); Bristol-Myers Squibb (I); Codiak Biosciences; Codiak Biosciences (I); Constellation Pharmaceuticals; Forty Seven; Forty Seven (I); Hummingbird; Hummingbird (I); ImaginAb; ImaginAb (I); Jounce Therapeutics; Jounce Therapeutics (I); Marker Therapeutics; Marker Therapeutics (I); Merck; Merck (I); Neon Therapeutics; Neon Therapeutics (I); Oncolytics; Pieris Pharmaceuticals; Polaris; Polaris (I); TapImmune Inc.; TapImmune Inc. (I); Tvardi Therapeutics (I)
Patents, Royalties, Other Intellectual Property - Own patent licensed to Jounce; Own patents licensed to BMS, Jounce & Merck (I)